GLAXOGlaxoSmithKline Pharmaceuticals Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • ROE: 49.1%
- • ROCE: 54.2%
- • Debt/Equity: 0.01
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 30
- • 6-month vs NIFTY: +13.2% relative
- • RSI Oversold Reversal signal (setup quality 56%)
Bull case
- • ROE: 49.1%
- • ROCE: 54.2%
- • Debt/Equity: 0.01
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: 2.1% YoY
- • Profit growth: 5.7% YoY
- • RSI: 31
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: 2.1% YoY
- • Profit growth: 5.7% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹71.53). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.